Cargando…
Evaluation of Ruxolitinib versus Best Available Therapy in Treating Primary Myelofibrosis
OBJECTIVES: This study aimed to evaluate the effectiveness of ruxolitinib and compare it with the best available therapy in patients with primary myelofibrosis. Ruxolitinib is a Janus kinase inhibitor that is approved for the treatment of myelofibrosis. The therapeutic protocol has changed after the...
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Sultan Qaboos University Medical Journal, College of Medicine & Health Sciences
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9423752/ https://www.ncbi.nlm.nih.gov/pubmed/36072080 http://dx.doi.org/10.18295/squmj.8.2021.110 |